Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spirit Scientific CoROCO:7790 27 Debt-to-Equity is 0.11 as of Dec. 2025, which is 8% below its 10-year median of 0.12. GuruFocus rates ROCO:7790 with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 964 Biotechnology companies, Spirit Scientific Co ranks worse than 60.58% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Spirit Scientific Co's Debt-to-Equity or its related term are showing as below:
ROCO:7790'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.12 Max: 0.43
Current: 0.25
During the past 4 years, the highest Debt-to-Equity Ratio of Spirit Scientific Co was 0.43. The lowest was 0.08. And the median was 0.12.
ROCO:7790's Debt-to-Equity is ranked worse than 60.58% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs ROCO:7790: 0.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Spirit Scientific Co Debt-to-Equity Related Terms
Spirit Scientific Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Spirit Scientific Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spirit Scientific Co Debt-to-Equity Chart
Spirit Scientific Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Debt-to-Equity
0.31
0.11
0.08
0.11
Spirit Scientific Co Quarterly Data
Mar25
Jun25
Sep25
Dec25
Debt-to-Equity
-
-
0.11
0.11
ROCO:7790 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Spirit Scientific Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spirit Scientific Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spirit Scientific Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Spirit Scientific Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spirit Scientific Co (ROCO:7790) has a Debt-to-Equity of 0.11 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spirit Scientific Co and its competitors. This is near median its historical median of 0.12. Over the past decade, Spirit Scientific Co's Debt-to-Equity has ranged from 0.08 to 0.43. According to the industry distribution chart, Spirit Scientific Co ranks #584 out of 964 companies in the Biotechnology industry, placing it in the top 60.6%.
Is Spirit Scientific Co's Debt-to-Equity too high?
Spirit Scientific Co's current Debt-to-Equity of 0.11 is near median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.43. The Biotechnology industry median Debt-to-Equity is 0.16. Spirit Scientific Co's value of 0.11 is 29% below this industry median. Based on the distribution chart, Spirit Scientific Co ranks #584 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Spirit Scientific Co has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Spirit Scientific Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spirit Scientific Co ranks #584 out of 964 companies for Debt-to-Equity. This places Spirit Scientific Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Spirit Scientific Co's value of 0.11 is 29% below this benchmark. Historically, Spirit Scientific Co's own Debt-to-Equity has ranged from 0.08 to 0.43 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 0.16, Spirit Scientific Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spirit Scientific Co's current Debt-to-Equity of 0.11 is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spirit Scientific Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spirit Scientific Co's current Debt-to-Equity is 0.11, which is near median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spirit Scientific Co stock overvalued right now?
Spirit Scientific Co (ROCO:7790) has a current Debt-to-Equity of 0.11. The current Debt-to-Equity is 0.11, which is near median its 10-year median of 0.12 and 29% below the Biotechnology industry median of 0.16. Spirit Scientific Co's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Spirit Scientific Co (ROCO:7790), the current Debt-to-Equity is 0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spirit Scientific Co Ltd is engaged in precision regenerative medicine, specializing in platelet cryocrystallization technology and Bio Material Lyophilized Technology (BMLT). The company provides solutions for extracting high-concentration platelet growth factors, enabling safe, flexible, and long-term storage therapies. Spirit Biotech delivers cutting-edge autologous healing reagent preparation services, along with OEM and ODM models. With a focus on unmet medical needs, the company transforms patented technologies into scalable solutions, advancing the future of regenerative healthcare.
27GF Score
Get the complete analysis for ROCO:7790
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7790 has been successfully added to your 
